Navigation Links
Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
Date:4/6/2011

(such as cephalosporins and fluoroquinolones), older age (over 65) and exposure to emerging hyper-virulent strains (BI/NAP1/027, 078, 001) of C. difficile. The rise in incidence of CDI, along with high rates of both treatment failures and recurrences with current therapies has resulted in greater awareness and concern about CDI among medical professionals and public health officials. You may learn more about CDI at www.cdiinfo.org, a website of Optimer.

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a class of anti-infectives called lipopeptides. The Cubist clinical product pipeline currently consists of a Phase 2 program focused on the development of a novel cephalosporin to address certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms; and a Phase 2 program for the treatment of CDAD (Clostridium difficile-associated diarrhea). Cubist also is working on several pre-clinical programs being developed to address areas of significant medical needs. These include therapies to treat various serious bacterial infections, and agents to treat acute pain. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubist's web site at www.cubist.com.

About Optimer

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has two anti-infective product candidates in development, DIFICID™ (fidaxomicin) and Pruvel™ (prulifloxacin). DIFICID is a narrow spectrum antibiotic b
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
2. Trading Halted Today in Optimer Pharmaceuticals Stock
3. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
4. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
5. Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
6. Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
7. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results
8. Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
9. Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock
10. Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
11. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014  UBM Medica US announces ... online community for oncologists, presents exclusive slide shows dealing ... essential to quality cancer care. Cancer ... ONCOLOGY , offers news, blogs, and podcasts about the ... quality cancer care: , End-of-life care is ...
(Date:7/31/2014)...  A substantial share of pharmacy and therapeutics ... are included in formularies—say patient support resources from ... Manhattan Research study, Taking the Pulse® Formulary ... P&T committee members in hospitals, managed care organizations ... a high bar for these programs, requiring that ...
(Date:7/31/2014)... , July 31, 2014 For its ... California , Art,s-Way Scientific has earned a ... With competition in over 30 categories, MBI,s contest ... MBI members, which include building manufacturers, dealers, and product ... an excellent example the capability of our team," said ...
Breaking Medicine Technology:Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3Art's Way Scientific Earns Prestigious Modular Building Institute Award 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 3Art's Way Scientific Earns Prestigious Modular Building Institute Award 4
(Date:8/1/2014)... 2014 Lifeinsurancenomedicalexam.info has released a ... for clients who have high cholesterol levels. , ... and qualify for no medical exam life insurance. These ... background medical check-ups. , Since there are no medical ... will qualify in just a few minutes. However, this ...
(Date:8/1/2014)... Cincinnati, Ohio (PRWEB) August 01, 2014 ... in-home care for seniors, is honored to be recognized as ... prestigious award is given to home care providers who rank ... satisfaction categories, based on monthly satisfaction interviews conducted by Home ... recognize the leading home care businesses, the best of the ...
(Date:8/1/2014)... In recent years, minimally invasive aesthetic injectable procedures have ... women are seeking age-defying treatments. As Botulinum toxin ... a growing number of nonaesthetic health professionals have emerged ... Small, MD and Henry M. Spinelli, MD from the ... and Kathleen M. Kelly, MD from Columbia University in ...
(Date:8/1/2014)... 2014 CapsCanada, a leading provider ... a new K-CAPS® (HPMC capsules) manufacturing facility in ... plans last year while experiencing growing global demand ... Manager, “KCAPS® are currently sold in more than ... “Compared to other HPMC capsules, K-CAPS® have exceptional ...
(Date:8/1/2014)... MA (PRWEB) August 01, 2014 For ... even when memory is still within the normal range, ... warning signs of future decline. This merits a closer ... in the August 2014 Harvard Men's Health Watch ... that if they forget where their keys are they ...
Breaking Medicine News(10 mins):Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2Health News:Cincinnati Senior Care Company Receives 2014 Best of Home Care® Employer of Choice Award 2Health News:Plastic surgeons or nurses: Who are the better injectors? 2Health News:Worried About Changes in Your Memory? It's Worth A Closer Look, From the August 2014 Harvard Men's Health Watch 2
... Four-legged heroes -- cats, too -- are maintaining the veterinary ... most of America,s blood donors, JJ and Logan are unaware ... saved. , But over a three-year period, the two healthy ... numerous canine patients survive surgeries and illnesses to play "fetch" ...
... Colo., April 18 Mesa Laboratories,Inc., (Nasdaq: MLAB ... will participate in a Health-Care Trade Policy Mission led ... selected as one of 15 companies,to accompany Under Secretary ... purpose of the mission is to provide a forum ...
... ROSEVILLE, Calif., April 18 CoolTouch Inc., ... introduction,of their new CoolBlue Duet(TM) laser lipolysis suction ... CoolLipo(TM) 1320 laser system.,Using a standard liposuction cannula, ... in one action, which dramatically reduces,the time of ...
... Supermarket,Company is alerting customers to a voluntary recall by Chang ... a sell by date of April 19,2008 and a UPC ... recalled because of the possible presence of,Listeria bacteria. Contamination with ... public health., Upon being notified of the recall, Stop ...
... April 17 The state,s Life Sciences Discovery,fund ... phase 1 clinical-trials,program to test new therapies for ... this evening, the grant is among the first,funded ... novel therapies targeted to treat solid tumors, in,collaboration ...
... cancer may have an Achilles, heel, report suggests , , THURSDAY, ... forced metastatic melanoma into remission for the first time, report ... case involves a 79-year-old woman with melanoma tumors in several ... in a gene called KIT, so the patient was enrolled ...
Cached Medicine News:Health News:Donor Dogs Give the Gift of Life 2Health News:Donor Dogs Give the Gift of Life 3Health News:Donor Dogs Give the Gift of Life 4Health News:CoolTouch Introduces CoolBlue Duet(TM) Laser Lipolysis Suction Handpiece 2Health News:Life Sciences Discovery Fund Awards $2.2 Million to Support New Solid-Tumor Research Program 2Health News:Gleevec Pushes Advanced Melanoma Into Remission 2
... The RetCam II is a mobile, self-contained system ... office. It provides state-of-the-art Wide-Field Pediatric Retinal Imaging. ... entire exam and document almost the entire retina with ... RetCam II is our 3 CCD medical grade digital ...
... The new Riata ... physicians even more versatility ... high defibrillation thresholds (DFTs)., ... lead family allows physicians ...
... of use with high software functionality ... guided system for neurosurgery that is ... With a 50% usage rate and ... 500 physicians, VectorVision Cranial is the ...
... system delivers on the promise of ... the latest advancement in fluidics control ... Lomb Surgical offers CONCENTRIX™ Fluidics Control ... provide both flow and vacuum response. ...
Medicine Products: